Literature DB >> 6122463

Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.

M J Kerr, D W Harron, C Kinney, R G Shanks.   

Abstract

1 Observations were made in five healthy subjects who exercised before and 2, 3, 6, 8 and 24 h after the oral administration on separate occasions of 160 mg oxprenolol, 160 mg slow release oxprenolol, 160 mg slow release oxprenolol with 0.25 mg cyclopenthiazide and placebo. Blood samples were obtained before and at 1, 2, 3, 6, 8, 12 and 24 h after drug administration and assayed for oxprenolol concentration. 2 The three formulations produced maximum reductions of 29% in the exercise tachycardia 3 to 6 h after drug administration. At 24 h the effects of the three preparations were not significantly different from placebo. 3 There were no significant differences in the plasma concentrations produced by the three formulations during the 24 h period. 4 These observations suggest that the slow release formulations of oxprenolol should be given twice daily to maintain cardiac beta-adrenoceptor blockade throughout a period of 24 h.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6122463      PMCID: PMC1401942          DOI: 10.1111/j.1365-2125.1981.tb01323.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Experience with a slow-release formulation of oxprenolol.

Authors:  H J Waal-Manning; G F Spears
Journal:  N Z Med J       Date:  1978-04-12

2.  Beta-blockers: once or three times a day?

Authors:  T Reybrouck; A Amery; R Fagard; P Jousten; P Lijnen; E Meulepas
Journal:  Br Med J       Date:  1978-05-27

3.  Once daily versus twice daily beta-blockers: effects on arrhythmias and hypertension.

Authors:  M H Frick; R Kala
Journal:  Lancet       Date:  1980-09-13       Impact factor: 79.321

4.  Atenolol and bendrofluazide in hypertension.

Authors:  J C Petrie; D B Galloway; J Webster; W T Simpson; J A Lewis
Journal:  Br Med J       Date:  1975-10-18

5.  Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol.

Authors:  W J Leahey; J D Neill; M P Varma; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

6.  Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA).

Authors:  D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

7.  Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.

Authors:  W J Leahey; J D Neill; M P Varma; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

8.  Once daily propranolol in the treatment of mild to moderate hypertension: a dose range finding study.

Authors:  A P Douglas-Jones; N S Baber; A Lee
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

9.  Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.

Authors:  J C Petrie; T A Jeffers; O J Robb; A K Scott; J Webster
Journal:  Br Med J       Date:  1980-06-28

10.  Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension.

Authors:  A J Marshall; D W Barritt; J Pocock; S T Heaton
Journal:  Lancet       Date:  1977-02-05       Impact factor: 79.321

View more
  2 in total

Review 1.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 2.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.